Fixed-dose macitentan-tadalafil polypill outperforms monotherapies in PAH

A visualization of the cardio-pulmonary system [Adobe Stock]

Pulmonary arterial hypertension (PAH) is a relatively rare disorder, affecting roughly 15 to 50 people per million within the U.S. and Europe. Treating it with a single therapy can be challenging, and medication adherence often presents a common hurdle for the condition. Combination therapy has thus become a widely used option in the treatment of the condition, as the American Journal of Cardiovascular Drugs noted in 2018. The 2022 guidelines from the European Respiratory Society and European Society for Cardiology (ERS/ESC) further support the combination approach, emphasizing the importance of initial combination therapy in personalized PAH treatment strategies.

The promise of a macitentan-tadalafil polypill

Highlighted in The Journal of the American College of Cardiology, the DUE study focused on a once-daily, single-tablet combination of macitentan…

Read more
  • 0

Five pharmaceuticals featured on Time’s list of top inventions alongside other medical breakthroughs

[Adobe Stock]

Time magazine’s most recent roundup of 200 inventions included an array of product types, spanning household gadgets and AI applications. Five distinct pharmaceuticals also made the list, not counting a shipping container for biologics and a vaccine for bees. Among the notable pharmaceutical advances on the list are a novel postpartum depression drug, a novel Alzheimer’s therapy, the first FDA-approved RSV vaccine, a blockbuster drug for diabetes and obesity that has driven record-breaking sales for Novo Nordisk. Outside of pharmaceuticals, other medical products that made Time’s list include advanced prosthetic limbs and portable diagnostic devices. Read on to see which pharmaceutical products won the attention of one of the most influential magazines in the U.S.

Zurzuvae, a new PPD treatment option

Zuranolone molecule image from PubChem

Read more
  • 0